IRIX
IRIDEX CORP
$1.11
+1.83%
$19.5M
No data for this timeframe.
Vol
Market Cap$19.5M
Cap SizeNano Cap
Inst. Holders3 funds
Inst. Value$1.1M
Inst. Activity0 buys / 1 sells
Insider Activity9B / 0S
Insider Net $$23.2K
SEC Reports2
Press Releases3
Exchange Nasdaq·Sector Electromedical & Electrotherapeutic Apparatus·Inc. DE·CIK 0001006045·Prev Close $1.09
Recent Activity
Jun 9, 2026
other
Iridex to Present at the Planet MicroCap Las Vegas 2026 Conference
<p align="left">MOUNTAIN VIEW, Calif., June 09, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasda
Jun 8, 2026
Insider
Dizon Romeo R bought 2,400 shares
Chief Financial Officer @ $1.12 ($2.7K)
Jun 5, 2026
Insider
Dizon Romeo R bought 2,521 shares
Chief Financial Officer @ $1.15 ($2.9K)
Jun 3, 2026
Insider
Dizon Romeo R bought 2,400 shares
Chief Financial Officer @ $1.17 ($2.8K)
May 19, 2026
SEC
IRIDEX reported Q1 2026 revenue of $11.8M, down 1% YoY, while net loss improved to $0.5M from $1.7M. The company reaffir
8-K — Impact 4/10
Apr 24, 2026
SEC
IRIDEX Corporation filed a definitive proxy statement (DEFA14A) for its 2026 annual stockholders' meeting, scheduled for
DEFA14A — Impact 3/10
Inst.
BANK OF AMERICA CORP — NEAR_EXIT
127 shares ($144.00)
Inst.
BANK OF AMERICA CORP — DOUBLED
622 shares ($709.00)
Price Targets
Historical data — last covering-analyst action May 2024. No current recommendation available.
$2.75 (May 2024)
Current $1.12
Low $2.75
Median $2.75
High $2.75
1 analysts
$2.75
$2.75
Analyst Ratings
2Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 15, 2024 | Stifel | MAINTAIN | Hold → Hold |
| Aug 26, 2022 | Stifel | DOWNGRADE | Buy → Hold |
| May 12, 2021 | Roth Capital | MAINTAIN | Buy |
| Mar 3, 2021 | Roth Capital | MAINTAIN | Buy |
| Jan 13, 2021 | Roth Capital | MAINTAIN | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.01 ▲ +50.0% | $-0.01 — $-0.01 | 1 | |
| Next Q | $-0.02 ▲ +33.3% | $-0.02 — $-0.02 | 1 | |
| Current FY | $-0.05 ▲ +58.3% | $-0.05 — $-0.05 | 72% YoY | 1 |
| Next FY | $0.02 | $0.02 — $0.02 | 140% YoY | 1 |
Latest Reports
NEUTRAL
8-K
4/10
IRIDEX reported Q1 2026 revenue of $11.8M, down 1% YoY, while net loss improved to $0.5M from $1.7M. The company reaffir
May 19, 2026
NEUTRAL
DEFA14A
3/10
IRIDEX Corporation filed a definitive proxy statement (DEFA14A) for its 2026 annual stockholders' meeting, scheduled for
Apr 24, 2026
NEUTRAL
Press
4/10
IRIDEX Corporation announced a partnership with EyeProGPO, granting preferred pricing on its retina laser products to ov
Apr 7, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $659.7K | — |
| RENAISSANCE TECHNOLOGIES LLC | $423.6K | — |
| BANK OF AMERICA CORP | $144.00 | NEAR_EXIT |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 8, 2026 | Dizon Romeo | BUY | $2.7K |
| Jun 5, 2026 | Dizon Romeo | BUY | $2.9K |
| Jun 3, 2026 | Dizon Romeo | BUY | $2.8K |
| May 26, 2026 | Mercer Patrick | F | $19.4K |
| May 26, 2026 | Dizon Romeo | BUY | $5.0K |
3 institutional holders with $1.1M total value (950,398 shares) as of 2025-Q4. Top holders: VANGUARD, RENAISSANCE, BANK. Net selling activity: 1 institutions trimmed/exited vs 0 added.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 578,711 | $659.7K | 60.9% | — |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 371,560 | $423.6K | 39.1% | — |
| 3 | BANK OF AMERICA CORP /DE/ | 127 | $144.00 | 0.0% | NEAR_EXIT -79.6% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 622 | 127 | -79.6% | $144.00 | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 123 | 622 | +405.7% | $709.00 | 2025-Q3 |
| UBS Group AG | NEAR_EXIT | 12,309 | 1,502 | -87.8% | $1.5K | 2025-Q1 |
3 unique insiders with 9 transactions. Net insider value: $23.2K ($23.2K bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 8, 2026 | Dizon Romeo R | Chief Financial Officer | BUY | 2,400 | $1.12 | $2.7K |
| Jun 5, 2026 | Dizon Romeo R | Chief Financial Officer | BUY | 2,521 | $1.15 | $2.9K |
| Jun 3, 2026 | Dizon Romeo R | Chief Financial Officer | BUY | 2,400 | $1.17 | $2.8K |
| May 26, 2026 | Mercer Patrick | President and CEO | F | 19,233 | $1.01 | $19.4K |
| May 26, 2026 | Dizon Romeo R | Chief Financial Officer | BUY | 5,004 | $1.00 | $5.0K |
| Apr 1, 2026 | Novel Inspiration International Co., Ltd. | 10%+ Owner | J | 87,949 | $0.00 | $0.00 |
| Mar 6, 2026 | Dizon Romeo R | Chief Financial Officer | BUY | 1,110 | $1.26 | $1.4K |
| Feb 17, 2026 | Dizon Romeo R | Chief Financial Officer | BUY | 1,000 | $1.37 | $1.4K |
| Feb 12, 2026 | Dizon Romeo R | Chief Financial Officer | BUY | 1,500 | $1.43 | $2.1K |
| Feb 10, 2026 | Dizon Romeo R | Chief Financial Officer | BUY | 1,000 | $1.46 | $1.5K |
| Feb 3, 2026 | Dizon Romeo R | Chief Financial Officer | BUY | 2,500 | $1.38 | $3.4K |
2 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 2 neutral. Avg impact: 3.5/10.
NEUTRAL
4/10
IRIDEX Corporation announced a partnership with EyeProGPO, granting preferred pricing on its retina
Apr 7, 2026
MIXED
6/10
IRIDEX Corporation reported strong Q4 and full-year 2025 results with 16% YoY revenue growth in the
Mar 26, 2026
NEUTRAL
3/10
IRIDEX Corporation announced plans to release its fourth quarter and full-year 2025 financial result
Mar 12, 2026
Historical analyst distribution (last covering-analyst action May 2024): 86% buy across 7 analysts — 2 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action May 2024. No current recommendation available.
$2.75 mean target (May 2024)
$2.75 Low
$2.75 High
| Metric | Value |
|---|---|
| Current Price | $1.12 |
| Target Low | $2.75 |
| Target Mean | $2.75 |
| Target Median | $2.75 |
| Target High | $2.75 |
| # Analysts | 1 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.01 | $-0.01 | $-0.01 | — | +50.0% | 1↑ 0↓ | $0.0B | — | 1 |
| Next Q 2026-09-30 |
$-0.02 | $-0.02 | $-0.02 | — | +33.3% | 1↑ 0↓ | $0.0B | — | 1 |
| Current FY 2026-12-31 |
$-0.05 | $-0.05 | $-0.05 | 72.4% | +58.3% | 1↑ 0↓ | $0.1B | 0.6% | 1 |
| Next FY 2027-12-31 |
$0.02 | $0.02 | $0.02 | 140.0% | — | 1↑ 0↓ | $0.1B | 7.1% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.010 | |
| 7d ago | $-0.020 | +0.010 |
| 30d ago | $-0.020 | +0.010 |
| 60d ago | $0.000 | -0.010 |
| 90d ago | $0.000 | -0.010 |
3 analyst firms have rated this stock: 0 upgrades, 1 downgrades, 3 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 15, 2024 | Stifel | MAINTAIN | Hold | Hold |
| Aug 26, 2022 | Stifel | DOWNGRADE | Buy | Hold |
| May 12, 2021 | Roth Capital | MAINTAIN | — | Buy |
| Mar 3, 2021 | Roth Capital | MAINTAIN | — | Buy |
| Jan 13, 2021 | Roth Capital | MAINTAIN | — | Buy |
| May 12, 2020 | Stifel | MAINTAIN | — | Buy |
| Jan 4, 2019 | Stifel | MAINTAIN | Buy | Buy |
| Oct 26, 2018 | Stifel | INITIATE | — | Buy |
| Dec 21, 2016 | Roth Capital | INITIATE | — | Buy |
| Jan 26, 2016 | Singular Research | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| May 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Apr 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Mar 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Jan 1, 2025 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Dec 1, 2024 | 0 | 0 | 3 | 1 | 2 | 0% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 9, 2026
other
Iridex to Present at the Planet MicroCap Las Vegas 2026 Conference
<p align="left">MOUNTAIN VIEW, Calif., June 09, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative
May 19, 2026
earnings
Iridex Reports First Quarter 2026 Financial Results
2026 Guidance Affirmed <pre>2026 Guidance Affirmed</pre>
May 19, 2026
earnings_calendar
IRIX Q1 2026 Earnings Scheduled — 2026-05-19
May 7, 2026
earnings_calendar
IRIX Q1 2026 Earnings Scheduled — 2026-05-07
May 5, 2026
earnings
Iridex to Report First Quarter 2026 Financial Results on May 19, 2026
<p>MOUNTAIN VIEW, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile
Apr 7, 2026
contract
Iridex Announces New Partnership with EyeProGPO to Expand Member Access to Retina Laser Technology
<p align="left">MOUNTAIN VIEW, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative
Mar 26, 2026
earnings
Iridex Reports Fourth Quarter and Full Year 2025 Financial Results
Strong Q4 and Full Year 2025 Revenue Performance Underpinned by Continued Operational Efficiencies <pre>Strong Q4 and Full Year 2025 Revenue Performan
Mar 26, 2026
earnings_calendar
IRIX Q4 2025 Earnings After Market Close — 2026-03-26
Mar 12, 2026
earnings
Iridex to Report Fourth Quarter and Full Year 2025 Financial Results on March 26, 2026
<p>MOUNTAIN VIEW, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatil
Mar 5, 2026
earnings_calendar
IRIX Q4 2025 Earnings After Market Close — 2026-03-05